Cutaneous laser treatment of port-wine stains and its impact on ocular manifestations in Sturge–Weber syndrome - Top-Institutions - MDSpire

Cutaneous laser treatment of port-wine stains and its impact on ocular manifestations in Sturge–Weber syndrome

  • By

  • Susan Darby Keith

  • Grace Herrick

  • Ashton Arlen

  • Halrleen K. Multani

  • Kelly Frasier

  • Kathryn Dempsey

  • Paul McDaniel

  • June 30, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Dermatology
    • Ophthalmology

  • #2

    University of California, Irvine
    University of California, Irvine

    Irvine, California

    Key Differentiators

    • Dermatology
    • Ophthalmology

  • #3

    John A. Moran Eye Center, University of Utah
    John A. Moran Eye Center, University of Utah

    Salt Lake City, Utah

    Key Differentiators

    • Ophthalmology

  • #4

    Alan S. Crandall Center for Glaucoma Innovation
    Alan S. Crandall Center for Glaucoma Innovation

    Salt Lake City, Utah

    Key Differentiators

    • Ophthalmology

  • #5

    University of Chicago
    University of Chicago

    Chicago, Illinois

    Key Differentiators

    • Ophthalmology

Original Source(s)

Cutaneous laser treatment of port-wine stains and its impact on ocular manifestations in Sturge–Weber syndrome

  • by Susan Darby Keith, Grace Herrick, Ashton Arlen, Halrleen K. Multani, Kelly Frasier, Kathryn Dempsey, Paul McDaniel

  • June 30, 2026

Related Content

Intralesional ALA-PDT for residual extramammary Paget's disease: a case report

AI Model Trails Expert Skin Lesion Readers

A foundation artificial intelligence model surpassed less experienced physicians but did not outperform expert dermatologists in multiclass skin lesion diagnosis.

Letter to the Editor Regarding “Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis”